Daniel Berger

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Novo Nordisk
    Topic:
    to FDA approved treatments for diabetes and FDA approved continuous glucose monitoring systems for diabetes
    Date added:
    06/17/2025
    Date updated:
    06/17/2025
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Astra Zeneca
    Topic:
    to FDA approved treatments for diabetes and FDA approved continuous glucose monitoring systems for diabetes
    Date added:
    06/17/2025
    Date updated:
    06/17/2025
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Dexcom
    Topic:
    to FDA approved treatments for diabetes and FDA approved continuous glucose monitoring systems for diabetes
    Date added:
    06/17/2025
    Date updated:
    06/17/2025
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Abbott
    Topic:
    Abbott
    Date added:
    06/17/2025
    Date updated:
    06/17/2025
Return to 0537_Sansum_APC Quarterly Educational Session: Management of Diabetes in People with Vascular Disease_ Live